Cellerys AG announces start of immune tolerance trial RED4MS trial in multiple sclerosis
17-06-2024 – This important trial will be conducted in 4 countries across Europe and aims to demonstrate the power of immune tolerizing approaches for patients with multiple sclerosis.
This phase of its RED4MS trial is intended to clarify how safe, tolerable and efficacy of the cell therapy called CLS12311 in patients with multiple sclerosis.
Cellerys AG (formerly known as ETIMSred) was previously accelerating at Wyss Zurich from 2015 to 2022. In June 2021, Cellerys AG signed a cooperation agreement with Novartis.
More info about the study.
